COVID-19 Alters But Doesn’t Change M&A Machine In 2020
$12bn Viatris Merger Completes In Remarkable Year
Executive Summary
Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.
You may also be interested in...
AmerisourceBergen Strikes $6.5bn Deal For Alliance
AmerisourceBergen has struck a $6.5bn deal to acquire the majority of the Alliance Healthcare businesseses from Walgreens Boots Alliance, giving it access to Alliance’s generics assets in Europe.
Siegfried Achieves Desired Scale After Completing Novartis Plant Deal
Siegfried has completed the acquisition of two Spanish manufacturing facilities from Novartis, in a move that will significantly enhance the Swiss CDMO’s capacity.
Alexion To Join With AZ Ahead Of US Soliris Biosimilars In 2025
Amgen will be able to launch its US Soliris biosimilar around two years ahead of patent expiry under a settlement agreement. The brand’s manufacturer, Alexion, discussed the threat as AstraZeneca pounced with a $39bn takeover agreement.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: